Table 7. Risk factors for subjective worsening of motor performance, anxiety, and insomnia identified by uni- and multivariate logistic regression analyses.
| Univariate model | Multivariate model | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of clinical cases/No. of total cases (%) | Unadjusted OR | P-value | Adjusted OR | P-value | ||||||||||
| Variable | 95%CI | Category | Overall | 95%CI | Category | Overall | ||||||||
| Subjective worsening of motor performance | ||||||||||||||
| Sex | ||||||||||||||
| Female | 8/14 (57.1) | 1 [reference] | - | 1 [reference] | - | |||||||||
| Male | 8/25 (32.0) | 0.35 | (0.09 | - | 1.36) | 0.131 | 0.60 | (0.11 | - | 3.20) | 0.547 | |||
| Age | ||||||||||||||
| <70 | 6/11 (54.6) | 1 [reference] | - | 0.301 | 1 [reference] | - | 0.582 | |||||||
| 70–79 | 5/18 (27.8) | 0.32 | (0.07 | - | 1.54) | 0.126 | 0.39 | (0.05 | - | 2.80) | 0.307 | |||
| ≥80 | 5/10 (50.0) | 0.83 | (0.15 | - | 4.63) | 0.606 | 0.75 | (0.07 | - | 7.65) | 0.845 | |||
| Disease duration | ||||||||||||||
| < 5 | 7/22 (31.8) | 1 [reference] | - | 1 [reference] | - | |||||||||
| ≥ 5 | 9/17 (52.9) | 2.41 | (0.65 | - | 8.92) | 0.188 | 1.90 | (0.38 | - | 9.61) | 0.437 | |||
| HY stage | ||||||||||||||
| 0–2 | 4/12 (33.3) | 1 [reference] | - | 1 [reference] | - | |||||||||
| 3, 4 | 12/27 (44.4) | 1.60 | (0.39 | - | 6.62) | 0.517 | 3.68 | (0.39 | - | 34.3) | 0.253 | |||
| MDS-UPDRS part 2* | 1.06 | (0.97 | - | 1.15) | 0.217 | 1.02 | (0.93 | - | 1.12) | 0.694 | ||||
| Subjective worsening of anxiety | ||||||||||||||
| Sex | ||||||||||||||
| Female | 7/14 (50.0) | 1 [reference] | - | 1 [reference] | - | |||||||||
| Male | 5/25 (20.0) | 0.25 | (0.06 | - | 1.05) | 0.058 | 0.34 | (0.06 | - | 2.15) | 0.253 | |||
| Age | ||||||||||||||
| <70 | 4/11 (36.4) | 1 [reference] | - | 0.561 | 1 [reference] | - | 0.721 | |||||||
| 70–79 | 4/18 (22.2) | 0.50 | (0.09 | - | 2.62) | 0.287 | 1.18 | (0.12 | - | 12.04) | 0.719 | |||
| ≥80 | 4/10 (40.0) | 1.17 | (0.20 | - | 6.80) | 0.516 | 2.61 | (0.16 | - | 42.16) | 0.427 | |||
| Disease duration | ||||||||||||||
| < 5 | 5/22 (22.7) | 1 [reference] | - | 1 [reference] | - | |||||||||
| ≥ 5 | 7/17 (41.2) | 2.38 | (0.59 | - | 9.53) | 0.221 | 1.71 | (0.29 | - | 9.91) | 0.551 | |||
| HY stage | ||||||||||||||
| 0–2 | 3/12 (25.0) | 1 [reference] | - | 1 [reference] | - | |||||||||
| 3, 4 | 9/27 (33.3) | 1.50 | (0.32 | - | 6.94) | 0.604 | 2.12 | (0.17 | - | 26.69) | 0.561 | |||
| MDS-UPDRS part 2* | 1.06 | (0.97 | - | 1.16) | 0.218 | 1.03 | (0.93 | - | 1.15) | 0.552 | ||||
| Subjective worsening of insomnia | ||||||||||||||
| Sex | ||||||||||||||
| Female | 3/14 (21.4) | 1 [reference] | - | 1 [reference] | - | |||||||||
| Male | 2/25 (8.0) | 0.32 | (0.05 | - | 2.19) | 0.245 | 0.705 | (0.07 | - | 7.52) | 0.772 | |||
| Age | ||||||||||||||
| <70 | 3/11 (27.3) | 1 [reference] | - | 0.278 | 1 [reference] | - | 0.569 | |||||||
| 70–79 | 1/18 (5.6) | 0.16 | (0.01 | - | 1.75) | 0.302 | 0.19 | (0.01 | - | 4.16) | 0.412 | |||
| ≥80 | 1/10 (10.0) | 0.30 | (0.02 | - | 3.45) | 0.812 | 0.35 | (0.01 | - | 8.82) | 0.874 | |||
| Disease duration | ||||||||||||||
| < 5 | 3/22 (13.6) | 1 [reference] | - | 1 [reference] | - | |||||||||
| ≥ 5 | 2/17 (11.8) | 0.84 | (0.12 | - | 5.72) | 0.863 | 0.66 | (0.05 | - | 8.36) | 0.745 | |||
| HY stage | ||||||||||||||
| 0–2 | 2/12 (16.7) | 1 [reference] | - | 1 [reference] | - | |||||||||
| 3, 4 | 3/27 (11.1) | 0.63 | (0.09 | - | 4.32) | 0.634 | 1.90 | (0.08 | - | 38.5) | 0.676 | |||
| MDS-UPDRS part 2* | 1.09 | (0.97 | - | 1.23) | 0.131 | 1.11 | (0.96 | - | 1.28) | 0.172 | ||||
Abbreviations: Unadjusted OR, Unadjusted odds ratio; 95%CI, 95% confidence interval; HY, Hoehn & Yahr; MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
* Continuous quantity was analyzed.